PT1713543E - Utilização de derivados de indolizina 1,2,3-substituídos para o tratamento de doenças relacionadas com uma angiogénese patológica coroidal - Google Patents
Utilização de derivados de indolizina 1,2,3-substituídos para o tratamento de doenças relacionadas com uma angiogénese patológica coroidal Download PDFInfo
- Publication number
- PT1713543E PT1713543E PT05717556T PT05717556T PT1713543E PT 1713543 E PT1713543 E PT 1713543E PT 05717556 T PT05717556 T PT 05717556T PT 05717556 T PT05717556 T PT 05717556T PT 1713543 E PT1713543 E PT 1713543E
- Authority
- PT
- Portugal
- Prior art keywords
- alk
- alkyl
- alkoxy
- coor
- carboxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0401094A FR2865934B1 (fr) | 2004-02-05 | 2004-02-05 | Utilisation de derives d'indolizine 1,2,3 substitues, inhibiteurs des fgfs, pour la preparation de medicaments utiles pour le traitement de maladies liees a une angiogenese pathologique choroidienne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1713543E true PT1713543E (pt) | 2009-12-15 |
Family
ID=34778525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT05717556T PT1713543E (pt) | 2004-02-05 | 2005-02-04 | Utilização de derivados de indolizina 1,2,3-substituídos para o tratamento de doenças relacionadas com uma angiogénese patológica coroidal |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8034828B2 (pt) |
| EP (1) | EP1713543B1 (pt) |
| JP (1) | JP5268258B2 (pt) |
| KR (1) | KR101199730B1 (pt) |
| CN (1) | CN1917922B (pt) |
| AT (1) | ATE448003T1 (pt) |
| AU (1) | AU2005216671B2 (pt) |
| BR (1) | BRPI0507509A (pt) |
| CA (1) | CA2553895C (pt) |
| CY (1) | CY1109669T1 (pt) |
| DE (1) | DE602005017581D1 (pt) |
| DK (1) | DK1713543T3 (pt) |
| ES (1) | ES2335900T3 (pt) |
| FR (1) | FR2865934B1 (pt) |
| HK (1) | HK1101065A1 (pt) |
| HR (1) | HRP20100030T1 (pt) |
| IL (1) | IL177088A (pt) |
| PL (1) | PL1713543T3 (pt) |
| PT (1) | PT1713543E (pt) |
| SI (1) | SI1713543T1 (pt) |
| WO (1) | WO2005082457A2 (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| SG158147A1 (en) * | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2270043A1 (en) | 2009-07-03 | 2011-01-05 | Sanofi-Aventis | Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor |
| FR2962438B1 (fr) * | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'indolizines, procedes de preparation et application en therapeutique |
| FR2962437B1 (fr) | 2010-07-06 | 2012-08-17 | Sanofi Aventis | Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2838123B1 (fr) * | 2002-04-04 | 2005-06-10 | Sanofi Synthelabo | Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf |
-
2004
- 2004-02-05 FR FR0401094A patent/FR2865934B1/fr not_active Expired - Fee Related
-
2005
- 2005-02-04 CA CA2553895A patent/CA2553895C/fr not_active Expired - Fee Related
- 2005-02-04 DK DK05717556.4T patent/DK1713543T3/da active
- 2005-02-04 BR BRPI0507509-2A patent/BRPI0507509A/pt not_active IP Right Cessation
- 2005-02-04 EP EP05717556A patent/EP1713543B1/fr active Active
- 2005-02-04 AU AU2005216671A patent/AU2005216671B2/en not_active Ceased
- 2005-02-04 AT AT05717556T patent/ATE448003T1/de active
- 2005-02-04 WO PCT/FR2005/000253 patent/WO2005082457A2/fr active Application Filing
- 2005-02-04 PT PT05717556T patent/PT1713543E/pt unknown
- 2005-02-04 DE DE602005017581T patent/DE602005017581D1/de active Active
- 2005-02-04 PL PL05717556T patent/PL1713543T3/pl unknown
- 2005-02-04 JP JP2006551884A patent/JP5268258B2/ja active Active
- 2005-02-04 CN CN2005800041509A patent/CN1917922B/zh not_active Expired - Fee Related
- 2005-02-04 SI SI200530900T patent/SI1713543T1/sl unknown
- 2005-02-04 KR KR1020067017920A patent/KR101199730B1/ko not_active IP Right Cessation
- 2005-02-04 ES ES05717556T patent/ES2335900T3/es active Active
-
2006
- 2006-07-25 IL IL177088A patent/IL177088A/en not_active IP Right Cessation
-
2007
- 2007-08-13 HK HK07108749.0A patent/HK1101065A1/xx not_active IP Right Cessation
-
2008
- 2008-08-29 US US12/201,075 patent/US8034828B2/en active Active
-
2009
- 2009-12-09 CY CY20091101327T patent/CY1109669T1/el unknown
-
2010
- 2010-01-18 HR HR20100030T patent/HRP20100030T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE448003T1 (de) | 2009-11-15 |
| PL1713543T3 (pl) | 2010-04-30 |
| US8034828B2 (en) | 2011-10-11 |
| CN1917922A (zh) | 2007-02-21 |
| IL177088A (en) | 2010-12-30 |
| JP2007520534A (ja) | 2007-07-26 |
| HK1101065A1 (pt) | 2007-10-05 |
| CA2553895A1 (fr) | 2005-09-09 |
| US20090030034A1 (en) | 2009-01-29 |
| IL177088A0 (en) | 2006-12-10 |
| FR2865934B1 (fr) | 2006-05-05 |
| FR2865934A1 (fr) | 2005-08-12 |
| DK1713543T3 (da) | 2010-03-22 |
| CA2553895C (fr) | 2013-04-02 |
| ES2335900T3 (es) | 2010-04-06 |
| SI1713543T1 (sl) | 2010-03-31 |
| EP1713543B1 (fr) | 2009-11-11 |
| CY1109669T1 (el) | 2014-08-13 |
| DE602005017581D1 (de) | 2009-12-24 |
| EP1713543A2 (fr) | 2006-10-25 |
| WO2005082457A2 (fr) | 2005-09-09 |
| AU2005216671B2 (en) | 2010-09-16 |
| JP5268258B2 (ja) | 2013-08-21 |
| CN1917922B (zh) | 2013-06-12 |
| KR101199730B1 (ko) | 2012-11-08 |
| WO2005082457A3 (fr) | 2005-11-10 |
| BRPI0507509A (pt) | 2007-06-26 |
| KR20070034986A (ko) | 2007-03-29 |
| HRP20100030T1 (hr) | 2010-03-31 |
| AU2005216671A1 (en) | 2005-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1101065A1 (pt) | ||
| BRPI0513750A (pt) | 2-fenilamino-benzamidas-5-substituìdas como inibidoras de mek | |
| MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
| MXPA03008223A (es) | Compuesto para tratamiento de enfermedades inflamatorias. | |
| SE0202462D0 (sv) | Novel use | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| ATE357453T1 (de) | Comt-inhibitoren | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| WO2007099302A8 (en) | Methods of maintaining oral health in animals using morpholine derivatives | |
| CY1109546T1 (el) | Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας | |
| WO2017027768A1 (en) | Compositions and methods for treating tuberculosis | |
| DE60127535D1 (de) | Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation | |
| DE60126199D1 (de) | Therapeutische behandlung von eosinophilie durch verwendung von chymase-inhibitoren als aktiven bestandteilen | |
| RU2005140156A (ru) | Применение аивлозина для лечения болезней, вызванных brachyspira pilosicoli или ornithobacterium rhinotracheale | |
| HK1080768A1 (en) | Use of epothilone derivatives for the treatment ofhyperparathyroidism | |
| TW200509917A (en) | Use of growth hormone secretagogues for treatment of fibromyalgia | |
| WO2008099853A1 (ja) | 歯周組織再生促進用医薬組成物及び歯周組織再生促進剤 | |
| TH69764A (th) | การใช้อนุพันธ์ของกรดฟีนอกซีอะซีติกสำหรับการรักษาภาวะกระเพาะปัสสาวะทำงานมากเกินไป |